Switch theme
Sign up to access all valuation multiples
Polaris Group is a multinational biotechnology company focused on developing novel anti-cancer therapies. The company's lead therapeutic Pegargiminase (ADI PEG 20), is a biologic in late-stage clinical development for a wide range of cancers, including hepatocellular carcinoma, mesothelioma, pancreatic cancer, non-small cell lung cancer, melanoma, acute myeloid leukemia and others. Polaris Group is also involved in every stage of the drug development process.
2014
n/a
Last FY Revenue $3.7M
Last FY EBITDA -$74.3M
$1.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Polaris Group achieved revenue of $3.7M and an EBITDA of -$74.3M.
Polaris Group expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Polaris Group valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $3.7M | XXX | XXX | XXX |
| Gross Profit | XXX | -$2.6M | XXX | XXX | XXX |
| Gross Margin | XXX | -72% | XXX | XXX | XXX |
| EBITDA | XXX | -$74.3M | XXX | XXX | XXX |
| EBITDA Margin | XXX | -2031% | XXX | XXX | XXX |
| EBIT | XXX | -$90.1M | XXX | XXX | XXX |
| EBIT Margin | XXX | -2462% | XXX | XXX | XXX |
| Net Profit | XXX | -$85.6M | XXX | XXX | XXX |
| Net Margin | XXX | -2339% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 2, 2025, Polaris Group's stock price is TWD 40 (or $1).
Polaris Group has current market cap of TWD 30.7B (or $1.0B), and EV of TWD 30.2B (or $1.0B).
See Polaris Group trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.0B | $1.0B | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 2, 2025, Polaris Group has market cap of $1.0B and EV of $1.0B.
Polaris Group's trades at 282.0x EV/Revenue multiple, and -13.9x EV/EBITDA.
Equity research analysts estimate Polaris Group's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Polaris Group's P/E ratio is not available.
See valuation multiples for Polaris Group and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EV (current) | $1.0B | XXX | $1.0B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 282.0x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -13.9x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -11.5x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -12.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -8.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialPolaris Group's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Polaris Group's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Polaris Group's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Polaris Group and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -2031% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 2049% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 2391% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Polaris Group acquired XXX companies to date.
Last acquisition by Polaris Group was XXXXXXXX, XXXXX XXXXX XXXXXX . Polaris Group acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Polaris Group founded? | Polaris Group was founded in 2014. |
| Where is Polaris Group headquartered? | Polaris Group is headquartered in Taiwan. |
| Is Polaris Group publicy listed? | Yes, Polaris Group is a public company listed on TAI. |
| What is the stock symbol of Polaris Group? | Polaris Group trades under 6550 ticker. |
| When did Polaris Group go public? | Polaris Group went public in 2016. |
| Who are competitors of Polaris Group? | Similar companies to Polaris Group include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Polaris Group? | Polaris Group's current market cap is $1.0B |
| Is Polaris Group profitable? | Yes, Polaris Group is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
